Floatz Rating
B60/100
Confidence
Indicative
Sponsor
GlaxoSmithKline
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06640049CT.gov A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China | — | Active Not Recruiting | — | — | — |
NCT05723562CT.gov A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer | — | Active Not Recruiting | — | — | — |
NCT04926324CT.gov A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Rectal Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dostarlimab (this asset) | GlaxoSmithKline | P2 | B · 60 |
| Oxaliplatin | Chongqing University Cancer Hospital | P3 | BB |
| Ertapenem | University of Ulm | P4 | BB |
| Fluorouracilum | Pei-Rong Ding | P3 | BB |
| Propofol | Uppsala University | P4 | BB |
| Sevoflurane | Uppsala University | P4 | BB |
| Capecitabine | Chongqing University Cancer Hospital | P3 | BB |
| Lidocaine | University of Illinois College of Medicine at Peoria | P4 | BB |
| Nepenthe | University of Illinois College of Medicine at Peoria | P4 | BB |
+36 more in the Rectal Neoplasm cohort
Other indications for Dostarlimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 68 |
| Ovarian Carcinoma | — | P3 | BB · 65 |
| Colonic Neoplasm | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dostarlimab in Rectal Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dostarlimab-rectal-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →